Back to search
PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome
Clinical trial pipeline · Data from ClinicalTrials.gov
See which PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome trials may be worth asking aboutClinical trial pipeline · Data from ClinicalTrials.gov
See which PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome trials may be worth asking aboutNorth America
Europe
Asia-Pacific
Rest of World
Trials may have sites in multiple countries. Filtering shows any trial with at least one site in the selected country.
This is a study of the safety and tolerability of oral miransertib (MK-7075) administered to participants at least 2 years of age with phosphatidylinositol-4,5-…
This is an open label, Phase 1/2 study of oral miransertib (MK-7075) administered to participants at least 2 years of age with phosphatidylinositol-4,5-bisphosp…
ARQ 092 is being investigated for patients with overgrowth diseases and/or vascular anomalies with genetic alterations of the PI3K/AKT pathway and may be availa…